TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10577447

Group type: EXPERIMENTAL
Intervention: 200 mg candoxatril twice a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg candoxatril twice a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20 mg frusemide twice a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Candoxatril
Number of subjects: 30
Study: 8984582

Group type: EXPERIMENTAL
Intervention: Guarana
Number of subjects: 45

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1752290

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg kg‐1 h‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bile acids (2 g ursodeoxycholic acid plus 2 g chenodeoxycholic acid)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes (4.2 g pancreatin)
Number of subjects: 10
Study: 7005678

Group type: EXPERIMENTAL
Intervention: Prednisolone (15 to 20 mg per day, maintenance dosage 10 mg per day)
Number of subjects: 51
Study: 31844133

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) training
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Diaphragm muscle training
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Abdominal muscle training
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 148
Study: 27720613

Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.1μg/kg/min
Number of subjects: 85

Group type: COMPARATOR
Intervention: Norepinephrine 0.05μg/kg/min
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100μg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ephedrine 5mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Emesis incidence
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hemodynamic parameters (heart rate, incidence of bradycardia, blood pressure, cardiac output, cardiac index, stroke volume, systemic vascular resistance, neonatal outcome)
Number of subjects: 85
Study: 25896832

Group type: EXPERIMENTAL
Intervention: hydrocortisone-bacitracin-colistin eardrops
Number of subjects: 230

Group type: COMPARATOR
Intervention: oral amoxicillin-clavulanate suspension
Number of subjects: 230

Group type: COMPARATOR
Intervention: initial observation
Number of subjects: 230
Study: 24239881

Group type: EXPERIMENTAL
Intervention: rTMS (1500 pulses; 1Hz; 90% of resting motor threshold for the first dorsal interosseous muscle) + Physical Therapy (PT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation + Physical Therapy (PT)
Number of subjects: 20
Study: 22923753

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Placebo (every 2 weeks)
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 1063
Study: 19947137

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 48

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 48
Study: 17553447

Group type: EXPERIMENTAL
Intervention: Acrylic intraocular lens (AMO Sensar; AR40e)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silicone intraocular lens (ClariFlex)
Number of subjects: 100
Study: 15367197

Group type: EXPERIMENTAL
Intervention: Collagen-BBM group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PLA-BBM group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Access flap procedure (AFP) group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Comparison between barrier groups (Collagen vs PLA)
Number of subjects: 34
Study: 11262536

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 40
Study: 9834045

Group type: EXPERIMENTAL
Intervention: N-0861 (specific doses administered via bolus and maintenance infusion)
Number of subjects: 19
Study: 7867873

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg, once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-release nifedipine (20 mg, twice daily)
Number of subjects: 0
Study: 2768542

Group type: EXPERIMENTAL
Intervention: Haloperidol (4-16 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amitriptyline (100-175 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 797593

Group type: EXPERIMENTAL
Intervention: Daktacort cream
Number of subjects: 63

Group type: COMPARATOR
Intervention: miconazole 2%
Number of subjects: 63

Group type: COMPARATOR
Intervention: hydrocortisone 1%
Number of subjects: 63
Study: 29528689

Group type: EXPERIMENTAL
Intervention: Maintenance Cognitive Stimulation Therapy (MCST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 48
Study: 28042732

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 0
Study: 26618457

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate-collagen filler
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaires
Number of subjects: 1008
Study: 21246281

Group type: EXPERIMENTAL
Intervention: Higher religiosity cohort (38 patients)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lower religiosity cohort (49 patients)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Males with higher religiosity
Number of subjects: 87
Study: 22049162

Group type: EXPERIMENTAL
Intervention: Lysine intake ranging from 15 to 240 mg · kg(‐1) · d(‐1)
Number of subjects: 21
Study: 19590022

Group type: EXPERIMENTAL
Intervention: GM-CSF (4 microg/kg/d) for 8 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 38
Study: 16816068

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 350
Study: 12624289

Group type: EXPERIMENTAL
Intervention: fMRI analysis after repetitive flexion-extension of the last 4 fingers of the right hand in migraine patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: fMRI analysis in healthy volunteers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Histogram analysis of normal-appearing WM in migraine patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Histogram analysis of normal-appearing WM in healthy volunteers
Number of subjects: 30
Study: 11707785

Group type: EXPERIMENTAL
Intervention: 3-injection technique (group 3N)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-injection technique (group 2N)
Number of subjects: 100
Study: 8961683

Group type: EXPERIMENTAL
Intervention: Cefonicid (single dose prophylactic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1461620

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (800 mg and 1,600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (160 mg)
Number of subjects: 0
Study: 4000864

Group type: EXPERIMENTAL
Intervention: Experimental subjects performing 45 trials in their respective training conditions (weight, distance, weight/distance)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study: 30342257

Group type: EXPERIMENTAL
Intervention: Wellness Champions for Change (WCC) and Wellness Champions for Change-Student (WCC-S)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Wellness Champions for Change (WCC) only
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Delayed intervention (Control)
Number of subjects: 1080
Study: 27651226

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 872

Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 872
Study: 24899557

Group type: EXPERIMENTAL
Intervention: One‐to‐one oral instruction strategy combined with an information sheet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular care following admission
Number of subjects: 60
Study: 22211669

Group type: EXPERIMENTAL
Intervention: Electronically delivered prescriptions
Number of subjects: 454

Group type: COMPARATOR
Intervention: Standard written prescriptions
Number of subjects: 454
Study: 20406780

Group type: EXPERIMENTAL
Intervention: Calculated non-SHBG bound oestradiol in girls
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Calculated non-SHBG bound testosterone in boys
Number of subjects: 663

Group type: COMPARATOR
Intervention: Assay measured non-SHBG bound oestradiol in girls
Number of subjects: 663

Group type: COMPARATOR
Intervention: Assay measured non-SHBG bound testosterone in boys
Number of subjects: 663
Study: 18547419

Group type: EXPERIMENTAL
Intervention: Compression treatment with special dressings
Number of subjects: 15

Group type: COMPARATOR
Intervention: Compression treatment with low‐adherence dressings and acupuncture
Number of subjects: 15
Study: 16205441

Group type: EXPERIMENTAL
Intervention: I.E.M. Mobilograph monitor
Number of subjects: 250

Group type: COMPARATOR
Intervention: Spacelabs 90207 monitor
Number of subjects: 250
Study: 11872893

Group type: EXPERIMENTAL
Intervention: Immunosuppressive and anticoagulant therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TCD ultrasonography monitoring
Number of subjects: 18
Study: 10455841

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1.5 mg.kg-1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketorolac 10 mg
Number of subjects: 60
Study: 7828316

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Early revascularization trial eligibility
Number of subjects: 251

Group type: COMPARATOR
Intervention: Early revascularization
Number of subjects: 251
Study: 2403867

Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (60 mg the first day and 20 mg on successive days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous infusion of isosorbide dinitrate and oral diltiazem
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined therapy of aspirin and vasodilators
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Full therapy including heparin and beta-blockers
Number of subjects: 41
Study: 552144

Group type: EXPERIMENTAL
Intervention: Pirbuterol 400 micrograms
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7046899

Group type: EXPERIMENTAL
Intervention: CVP
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CVP-A
Number of subjects: 131
Study: 31595667

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis knowledge assessment scale (RAKAS)
Number of subjects: 263
Study: 29136160

Group type: EXPERIMENTAL
Intervention: 875/125mg q12h
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 500/125mg q8h
Number of subjects: 29

Group type: COMPARATOR
Intervention: 500/125mg q12h
Number of subjects: 29

Group type: COMPARATOR
Intervention: 250/125mg q8h
Number of subjects: 29
Study: 26714411

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 657

Group type: COMPARATOR
Intervention: Both treatments (Acarbose and Metformin)
Number of subjects: 657
Study: 24582373

Group type: EXPERIMENTAL
Intervention: Large electrodes (35 cm2) at equivalent current density (0.014, 0.029, 0.043 mA/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small electrodes (16 cm2) at equivalent current density (0.014, 0.029, 0.043 mA/cm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large electrodes (35 cm2) at equal current intensity (0.5, 1.0, 1.5 mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small electrodes (16 cm2) at equal current intensity (0.5, 1.0, 1.5 mA)
Number of subjects: 0
Study: 21450574

Group type: EXPERIMENTAL
Intervention: Exercise training (CHF-E) for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary control group (CHF-S)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy subjects (HC)
Number of subjects: 24
Study: 20457737

Group type: EXPERIMENTAL
Intervention: Accelerated intervention with early therapeutic exercise
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard protection, rest, ice, compression, and elevation intervention
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 17495250

Group type: EXPERIMENTAL
Intervention: Thymosin beta-4 (Tbeta-4) administered topically
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 15642038

Group type: EXPERIMENTAL
Intervention: Poly L‐lactide acid‐polyglycolic acid test screws
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Titanium test screws
Number of subjects: 7
Study: 11999595

Group type: EXPERIMENTAL
Intervention: 1 microgkg(‐1) fentanyl (Group F)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 microgkg(‐1) alfentanil (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 microgkg(‐1) followed by an infusion of 0.5 pg kg min(‐1) remifentanil (Group R)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (Group P)
Number of subjects: 80
Study: 9787369

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (COSOPT) twice daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Timolol (TIMOPTIC) twice daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Dorzolamide (TRUSOPT) three times daily
Number of subjects: 253
Study: 7623395

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program with nicotine patches
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 2649221

Group type: EXPERIMENTAL
Intervention: CFP (cyclophosphamide, 5‐fluorouracil, prednisone)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, 5‐fluorouracil, methotrexate, prednisone)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CFP
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 336
Study: 381005

Group type: EXPERIMENTAL
Intervention: (‐)eburnamonine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: cinnarizine
Number of subjects: 106
Study: 30354794

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading 1 μg/kg over 20 min followed by infusion at 0.5 μg/kg/h)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control group)
Number of subjects: 38
Study: 28120248

Group type: EXPERIMENTAL
Intervention: CO2 laser (140 Hz, 400 μs, 33 mJ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Er:YAG laser (35 Hz, 297 μs, 200 mJ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 32

Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 32
Study: 26445862

Group type: EXPERIMENTAL
Intervention: Onstep technique
Number of subjects: 290

Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 290
Study: 23558107

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 64
Study: 22046182

Group type: EXPERIMENTAL
Intervention: Imidafenacin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 41
Study: 19563365

Group type: EXPERIMENTAL
Intervention: Cooled-tip catheter ablation
Number of subjects: 156

Group type: COMPARATOR
Intervention: 4-mm-tip catheter ablation
Number of subjects: 156
Study: 17678462

Group type: EXPERIMENTAL
Intervention: Psychological abuse (limited duration: 6 months-2 years)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Psychological abuse (prolonged duration: >2 years)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Sexual abuse without penetration
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Sexual abuse with penetration
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Abuse in adulthood
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Abuse in both adulthood and childhood
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Abuse in childhood only
Number of subjects: 547
Study: 14975380

Group type: COMPARATOR
Intervention: Intrathecal fentanyl (50 microg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (50 microg) plus fentanyl (50 microg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous remifentanil
Number of subjects: 32
Study: 10805823

Group type: EXPERIMENTAL
Intervention: Physiologic pacing
Number of subjects: 2568

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2568
Study: 9497116

Group type: EXPERIMENTAL
Intervention: Dual-switch valve (DSV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional differential-pressure (DP) valve
Number of subjects: 35
Study: 8382381

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (4 grams per 500 milligrams every eight hours)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (1 gram every eight hours)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 86

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 86
Study: 3017723

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30196789

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Aspirin 81 mg once daily
Number of subjects: 1100
Study: 28715608

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 24
Study: 25361054

Group type: EXPERIMENTAL
Intervention: Slow eating speed (30 minutes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fast eating speed (10 minutes)
Number of subjects: 25
Study: 23073729

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study: 22123713

Group type: EXPERIMENTAL
Intervention: Dose-dense TC with severe anemia (hemoglobin <8.0 g/dL)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Dose-dense TC without severe anemia (hemoglobin >8.0 g/dL)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Conventional TC with severe anemia
Number of subjects: 622

Group type: COMPARATOR
Intervention: Conventional TC without severe anemia
Number of subjects: 622
Study: 19592548

Group type: EXPERIMENTAL
Intervention: Sternal weave closure (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine sternal wire closure (Group B)
Number of subjects: 200
Study: 17215609

Group type: EXPERIMENTAL
Intervention: Weight management program using self-efficacy for 12 weeks
Number of subjects: 42
Study: 12772814

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by local‐regional radiotherapy
Number of subjects: 506

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 506
Study: 10799160

Group type: EXPERIMENTAL
Intervention: Antibiotics (rifampin, doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin, ciprofloxacin) for 18 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 18 weeks
Number of subjects: 50
Study: 9275368

Group type: EXPERIMENTAL
Intervention: Artesunate at a dose of 6 mg/kg once a week for 8 weeks
Number of subjects: 864

Group type: COMPARATOR
Intervention: Placebo with the same dose-schedule
Number of subjects: 864
Study: 1472342

Group type: EXPERIMENTAL
Intervention: Home-care assistance (HCA) provided by a multidisciplinary team of caregivers; duration: 6 months; involved palliative care.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ordinary hospital-based care (OC); duration: 6 months; included inpatient and outpatient services.
Number of subjects: 42
Study: 6853785

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate (BD) ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diflorasone diacetate (DD) ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 30814413

Group type: EXPERIMENTAL
Intervention: Okara (60 g/day for 2 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 27986347

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cetuximab (CTX)
Number of subjects: 33
Study: 25483421

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHD) solution, wiped till day seven of life
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lukewarm water, wiped till day seven of life
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHD) solution
Number of subjects: 140
Study: 24819981

Group type: EXPERIMENTAL
Intervention: Total urinary resveratrol metabolites (mean concentration 7.08 nmol/g of creatinine)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Lowest quartile of total urinary resveratrol metabolites
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Baseline total urinary resveratrol metabolites quartiles
Number of subjects: 783
Study: 22349666

Group type: EXPERIMENTAL
Intervention: Maximum Vasoactive Inotropic Score (VIS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low Cardiac Output Syndrome (LCOS)
Number of subjects: 76
Study: 20395261

Group type: EXPERIMENTAL
Intervention: Spirometry (lung function variables including FEV(1), FVC, FEV(1)/FVC)
Number of subjects: 532
Study: 17640545

Group type: EXPERIMENTAL
Intervention: New trials and therapies for treating STEMI
Number of subjects: 500000
Study: 16813032

Group type: EXPERIMENTAL
Intervention: Intranasal hypertonic Dead Sea saline spray
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intranasal aqueous triamcinolone spray
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 15